Altogether, these results suggest that SIRPα blockade therapy may only be applicable and of benefit when the tumor antigen GD2 is present on the surface of neuroblastoma cells in sufficient amounts and hence ADCC can be triggered upon antibody therapy with dinutuximab. Here, SIRPA is linked to neoplasm.